- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
The Scientific World Journal
Volume 2012 (2012), Article ID 145651, 6 pages
Simple Reversed-Phase HPLC Method with Spectrophotometric Detection for Measuring Acetaminophen-Protein Adducts in Rat Liver Samples
Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John’s University, Jamaica, NY 11439, USA
Received 15 October 2011; Accepted 1 December 2011
Academic Editors: R. Hughes and T. Weiss
Copyright © 2012 Miteshkumar Acharya and Cesar A. Lau-Cam. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A simple reversed-phase HPLC method for measuring hepatic levels of acetaminophen- (APAP-) protein adduct following an overdose of APAP was developed. An aliquot of liver homogenate in phosphate-buffered saline pH 7.4 (PBS) was placed on a Nanosep centrifugal device, which was centrifuged to obtain a protein residue. This residue was incubated with a solution of p-aminobenzoic acid (PABA), the internal standard, and bacterial protease in PBS, transferred to a Nanosep centrifugal device, and centrifuged. A 100 μL portion of the filtrate was analyzed on a YMC-Pack ODS-AMQ C18 column, using 100 mM potassium dihydrogen phosphate-methanol-acetic acid (100 : 0.6 : 0.1) as the mobile phase, a flow rate of 1 mL/min, and photometric detection at 254 nm. PABA and APAP-cystein-S-yl (APAP-Cys) eluted at ~14.7 min and 22.7 min, respectively. Method linearity, based on on-column concentrations of APAP-Cys, was observed over the range 0.078–40 μg. Recoveries of APAP-Cys from spiked blank liver homogenates ranged from ~83% to 91%. Limits of detection and of quantification of APAP-Cys, based on column concentrations, were 0.06 μg and 0.14 μg, respectively. RSD values for interday and intraday analyses of a blank liver homogenate spiked with APAP-Cyst at three levels were, in all cases, ≤1.0% and <1.5%, respectively. The proposed method was found appropriate for comparing the antidotal properties of N-acetylcysteine and taurine in a rat model of APAP poisoning.
In addition to being the most common analgesic and antipyretic agent worldwide, acetaminophen (N-acetyl-p-aminophenol, APAP) is also regarded as a leading cause for intentional or unintentional overdosing, for severe hepatotoxicity and for acute live failure (ALF) in the United States and the United Kingdom [1, 2]. One of the critical contributory steps to the hepatotoxicity that follows the ingestion of overdoses of APAP is its initial oxidative metabolism to N-acetyl-p-benzoquinoneimine (NAPQI) by hepatic cytochrome P450 isoforms and subsequent covalent binding of this reactive metabolite to hepatic cytosolic and organelle proteins, primarily, though, not exclusively, to cysteine residues to generate stable 3-(cystein-S-yl)acetaminophen (APAP-Cys) adducts . The extent to which APAP binds to hepatic proteins is of clinical interest since it reflects the severity of its dose-related damaging action on the liver, especially to centrilobular cells  and is a way to improve diagnostic accuracy in patients with ALF . Analytical methods presently available to measure APAP covalently bound to proteins in the liver and serum have included an avidin-biotin amplified competitive enzyme-linked immunosorbent (A-B ELISA) assay [6, 7], an immunoblot technique using antiserum specific for APAP-CYS and imaging densitometry [8, 9], and a high-performance liquid chromatography with coulometric electrochemical detection (HPLC-ECD) [5, 10]. While the A-B ELISA and immunoblot techniques require multiple procedural steps and reagents and an antiserum specific for APAP-Cys that is not readily available, the HPLC-ECD method relies on a lengthy dialysis step to separate protein-bound APAP from any interfering amino acids, unbound APAP, or free APAP-Cys and on an electrochemical detection setup that may not be available in the average laboratory. A more recently published liquid chromatographic method coupled with tandem mass spectrometric has only been evaluated as a qualitative tool for detecting the binding of APAP to serum albumin .
In comparison with currently available analytical methods for measuring APAP-protein conjugates in biological samples, the HPLC method with photometric detection described in the present report is methodologically simpler, requiring less procedural steps, and using readily available reagents. The sample preparation has been greatly simplified by utilizing centrifugal ultrafiltration to initially isolate APAP-protein adducts, and, subsequently, the APAP-Cys fragments liberated by enzymatic hydrolysis from their anchoring proteins. The method has been found to be specific, reproducible, and with the required sensitivity to detect the levels of APAP-Cys associated with an overdose of APAP. Using the rat as an experimental model, the proposed HPLC method was found to be not only useful for measuring APAP-protein adducts in the liver but also for assessing the antidotal effectiveness of model compounds against APAP-induced hepatotoxicity due to a toxic dose of APAP.
2.1. Materials and Solvents
APAP, p-aminobenzoic acid (PABA), potassium dihydrogen phosphate, and protease (Pronase E, type XIV from Streptomyces griseus, 4 units/mg of solid) were purchased from Sigma-Aldrich, St. Louis, MO, USA. 3-Cysteinylacetaminophen (APAP-Cys) trifluoroacetic acid salt was purchased from Toronto Research Chemicals Inc., North York, ON, Canada. HPLC-grade methanol, HPLC-grade water, perchloric acid (70%, w/v), and glacial acetic acid were purchased from J. T. Baker, Phillipsburg, NJ, USA. Nanosep centrifugal device with Omega ultrafiltration membrane molecular weight cutoff 30 kDa, red type, was from Pall Corporation, East Hills, NY, USA; and high-grade regenerated cellulose tubular dialysis membrane (Cellu-Sep H1, nominal MWCO 3500) was from Membrane Filtration Products, Inc., Seguin, TX, USA.
2.2. HPLC System
Chromatographic analyses were carried out on a Waters Alliance HPLC system consisting of the 2695 Separations Module, 2998 photodiode array detector and 2707 autosampler (Waters Corporation, Milford, MA, USA). The chromatograms were acquired with an Empower Chromatography Software (Waters Corporation, Milford, MA, USA).
2.3. Chromatographic Conditions
The chromatographic separations were achieved on an YMC-Pack ODS-AMQ C18, 150 × 4.6 mm i.d., 5 μm, column (Waters Corporation, Milford, MA, USA). The mobile phase was a mixture of 100 mM potassium dihydrogen phosphate-methanol-acetic acid (100 : 0.6 : 0.1, by volume), pH 4.7 ± 0.2, filtered in vacuo through a 0.45 μm membrane filter (Millipore, Bedford, MA, USA), and degassed by sonication prior to use. The mobile phase was delivered at a rate of 1 mL/min. A 100 μL volume of sample was injected from an autosampler kept at 4°C. The detection wavelength was 254 nm.
2.4.1. Protease Solution
This solution was prepared by dissolving a sample of lyophilized, powdered, bacterial protease in phosphate-buffered saline (PBS) pH 7.4 to obtain a solution containing 8 units per mL.
2.4.2. PABA Solution
This solution was prepared by dissolving a sample of PABA, the internal standard, in distilled water to obtain a solution containing 1 mg/mL.
2.5. Validation of the Method
2.5.1. Linearity and Recovery
The linearity of the proposed HPLC method was assessed by preparing two calibration curves, one in protein matrix and one in distilled water, from serial dilutions of an aqueous APAP-Cys stock solution (1 mg/mL). The protein matrix was obtained by placing 0.5 mL aliquots of a homogenate made from the liver of a rat treated only with 50% PEG on individual conditioned 30 kDa Nanosep centrifugal device (previously conditioned by wetting with 0.2 mL of distilled water and followed by drying by centrifugation at 12.000 ×g for 10 min) and subjecting the devices to centrifugation at 12.000 ×g for 10 min. The retained protein residues were quantitatively dislodged from the membranes by using 100 μL aliquots of distilled water, and all the washings were pooled together until a 4 mL volume of matrix protein dispersion had been collected. The entire volume of matrix protein dispersion and an equal volume of distilled water were separately mixed with 250 μL of PABA solution and 250 μL of protease solution. A 400 μL volume of each reaction mixture was mixed with 100 μL of APAP-Cys solution, and each type of solution was serially diluted, respectively, with blank stock matrix protein dispersion or distilled water to obtain concentrations of APAP-Cys in the range 1.562–200 μg/mL. Following their incubation at 50°C for 16 hr, the dilutions were filtered through 0.45 μm membrane filters, and a 100 μL aliquot of each filtrate was injected into the liquid chromatograph in duplicate.
The percentage (%) recovery of APAP-Cys from protein matrix was calculated from the peak area ratios gathered in the linearity study. To this effect, the peak area ratios at each dilution for samples prepared in protein matrix were related to those in water. Assuming the peak area ratios for solutions in water to represent 100% recovery, the recovery of APC-Cys from liver matrix protein at each level studied (as a percentage of the peak responses for samples in distilled water) was calculated using the equation (peak area ratio in matrix protein/peak area ratio in water) × 100.
2.5.2. Investigation of the Isolation of APAP-Protein Adducts from Liver Homogenates
Based on the peak area response obtained for an aqueous 10 μg/mL solution of APAP-Cys put through the sample preparation steps used in the linearity test and representing 100% recovery, three sample preparation approaches were examined to determine which one yielded the highest recovery. For this purpose, 100 μL aliquots of a stock solution of APAP-Cys containing 1 mg/mL were added to 400 μL of an incubation mixture obtained by one of three different approaches. The first approach was a centrifugal ultrafiltration method in which 4 mL of matrix protein obtained as described for the method linearity study was treated in the exactly the same manner as for a dilution sample containing a final concentration of APAP-Cys of 10 μg/mL in matrix protein. The second approach was a precipitation method whereby a 4 mL aliquot of drug-free liver homogenate, prepared in phosphate-buffered saline (PBS) pH 7.4 in a ratio of 1 g in 5 mL, was mixed with 400 μL of 10% perchloric acid and centrifuged at 12.000 ×g and 4°C for 20 min to obtain a protein pellet. This pellet was washed with two 200 μL portions of water, resuspended in 4 mL of 3 M urea in PBS pH 8.0, and subjected to sonication in an ultrasonic bath until a uniform dispersion was obtained. This suspension was then processed as described in the linearity study and starting with the consecutive addition of a PABA solution and a protease solution. The third approach was a dialysis method in which a 4 mL aliquot of drug-free liver homogenate, prepared in PBS pH 7.4 using a ratio of 1 g in 5 mL, was placed in a Cellu-Sep H1 tubular dialysis membrane and dialyzed three time against 1000 mL portions of sodium acetate buffer pH 6.5 for periods of 12 hr each. The contents of the dialysis bag were transferred to 4 mL of acetate buffer pH 6.5, and the dispersion was next processed as described in the linearity study and starting with the addition of PABA solution and protease solution.
2.5.3. Intraday and Interday Precision
Samples of APAP-Cys in matrix protein dispersion, prepared as described for the linearity and recovery study and containing 0.156, 0.625, and 1.25 μg of analyte per 100 μL, were injected at three different times in the same day to check for intraday reproducibility or at the same time in three separate days to check for interday reproducibility.
2.6. Animal Studies
Groups of 6 male Sprague-Dawley rats, 200–225 g in weight, were maintained on a normal rat chow and filtered tap water for 3 days following their arrival. Following a 12 hr fasting overnight, the animals received a single intraperitoneal (i.p.), 800 mg/kg/2 mL, dose of an APAP solution (100 mg/mL) in 50% PEG 400. Animals treated with an APAP antidote received either N-acetylcysteine (NAC) or taurine (TAU) in physiological saline by the i.p. route, in a 2.4 mmol/kg/2 mL dose, 30 min before APAP. Control animals received only 50% PEG 400 (2 mL) followed 30 min later by water (2 mL). After 6 hr, all the animals were sacrificed by decapitation, and their livers were freeze clamped, surgically excised, and placed in liquid nitrogen until needed.
2.7. Liver Sample Preparation
A 1 g portion of frozen liver was mixed with 5 mL of PBS pH 7.4 and homogenized for 30 sec with a hand-held electric tissue homogenizer while kept immersed in an ice bath. The resulting suspension was centrifuged at 12.000 ×g and 4°C for 20 min, and a 500 μL aliquot of the supernatant was placed on a Nanosep centrifugal device with a membrane molecular weight cutoff of 30 kDa (previously conditioned by wetting with 200 μL of distilled water and drying by centrifugation at 12,000 ×g for 10 min) and the device centrifuged at 12.000 ×g for 10 min. The protein retained on the membrane was washed three times with 100 μL portions of distilled water, with centrifugation at 12.000 ×g for 10 min after each washing, and then quantitatively dislodged from the membrane with the aid of a spatula and 100 μL portions of distilled water until a 400 μL volume of protein dispersion had been collected. This protein dispersion was mixed, in succession, with 25 μL of PABA solution (1 mg/mL) and 25 μL of protease solution (8 units/mL), and then incubated at 50°C for 16 hr on a heating block. The digest was transferred to a conditioned Nanosep centrifugal device and centrifuged at 12.000 ×g for 10 min to collect the filtrate. The membrane on the filtration device was rinsed twice with 100 μL portions of distilled water, and the washings and filtrate were pooled together and brought to a final volume of 700 μL with additional distilled water. A 100 μL aliquot of this solution was injected into the liquid chromatograph.
2.8. Data Analysis
The experimental results for the animal study are reported as the mean ± SEM for . Statistical comparisons were carried out using Student’s t-test followed by one-way analysis of variance (ANOVA) and Tukey’s test for multiple comparisons. Calculations were performed using a commercially available statistical software program (JMP 8 from SAS Institute Inc., Cary, NC, USA). Differences were considered to be significant when .
3. Results and Discussion
3.1. Isolation of APAP-Protein Conjugates
The most appropriate conditions to isolate APAP bound to hepatic proteins via the sulfhydryl side chains of cysteine residues from the liver of animals that had been treated with a supratherapeutic (800 mg/kg) of APAP were investigated using three general approaches: dialysis, chemical precipitation with a deproteinizing solution, and centrifugal ultrafiltration. In each case, the isolated APAP-protein conjugates were subjected to digestion with microbial protease, and the quantity of APAP-Cys thus liberated was measured by the proposed HPLC method. The results originating from these three experiments, carried out in triplicate, are graphically shown in Figure 1.
According to the sample preparation method described by Muldrew et al. , a 1 : 10 liver homogenate in 10 mM sodium acetate pH 6.5 is centrifuged at 16.000 ×g and dialyzed against a large volume (4 L) of the homogenizing medium using a dialysis membrane with a molecular mass cutoff of 3500 kDa. Subsequently, the contents of the dialysis bag are precipitated with 40% trichloroacetic acid, rinsed with disodium phosphate pH 7.4, and resuspended in 10 mM sodium acetate pH 6.5. In addition to the need for replacing the dialyzing medium twice (at 9 and 21 hr) and, hence, large volumes of dialyzing medium, this technique requires more than one day for completion. As shown in Figure 1, the recovery of APAP adduct by this method amounted to about 62% of the added amount. Although the exact reason for this deviation from maximum recovery is at present unclear, one potential contributory factor that will certainly require a more detailed investigation is the type of protease used in different laboratories to release APAP-Cys from its anchoring proteins since the activity of different types of protease can vary over a wide pH range . Thus, one would expect a higher yield of APA-Cys using the present type of protease (Pronase E from Streptomyces griseus) in a solution buffered with PBS than in one buffered with 10 mM solution of sodium acetate since the pH of the former buffer (i.e., pH 7.4) is closer to the pH declared as optimal (i.e., pH 7.5) by the supplier of this enzyme than is to that of the latter buffer (i.e., pH 6.5).
In an attempt to simplify the isolation of APAP-protein adducts from liver samples, the liver homogenate in PBS pH 7.4 was directly treated with a known protein precipitating agent such as 10% perchloric acid in methanol. The precipitated proteins, separating as a pellet upon centrifugation, were subjected to two cycles of dispersion in water followed by centrifugation and submitted to proteolytic digestion. Although extremely simple and fast, the recovery of APAP-Cys adduct by this protein-separating approach was slightly less (by ~3.7%) than that by dialysis (Figure 1), possibly because of the degree of compactness of the protein pellet and of the traces of acid remaining with it, factors which could have, respectively, interfered with the ability of the protease to reach all of the APAP-protein adducts available for proteolysis and for displaying its full hydrolyzing activity.
In the proposed method, APAP-protein adducts were isolated from liver homogenates in PBS pH 7.4 by centrifugal ultrafiltration using a Nanosep centrifugal device. In essence, this device will retain the APAP-protein adduct on the ultrafiltration membrane, which in this case was selected to retain adducts having a molecular weight of 30 kDa and above. The retentive efficiency and, hence, the quantity of APAP-protein adduct left on the membrane, amounted to about 90.0% (Figure 1). In addition to its simplicity and greater efficiency as an isolation technique, processing of a liver homogenate by this technique could be successfully completed in less than 1 hr.
3.2. Chromatographic Conditions
Using photometric detection at 254 nm, PABA, the internal standard, and APAP-CYS, the analyte, injected as part of an aqueous mixture, were observed to elute at about 14.5 and 23.3 min, respectively, (Figure 2(a)). A liver sample from a rat receiving only 50% PEG 400, and put through the ultrafiltration and proteolytic digestion steps, showed chromatographic peaks for endogenous liver components which did not interfere with the peaks of interest (Figure 2(b)). An identical chromatographic pattern was obtained from the analysis of a liver sample from a rat treated with a very high (800 mg/kg) dose of APAP (Figure 2(c)). Confirmatory evidence on the identity of the slower-eluting peak was obtained by spiking the same liver sample with authentic APAP-Cys (~5 μg/100 μL) and observing an enhancement in the size of the peak eluting at ~23.0 min (Figure 2(d)).
3.3. Linearity, Recovery, and Limits of Detection
The linearity of the proposed method was investigated by preparing two ten-point calibration curves for APAP-Cys, one in blank liver matrix protein and the other in distilled water. For both types of solutions, a linear correlation between peak area responses at 254 nm and on-column concentrations of APAP-Cys in the range 0.078–40.000 μg was observed.
By relating the peak area responses derived from solutions of APAP-Cys in blank liver matrix protein with those from solutions in distilled water, taken as 100% recovery, it was verified that the recovery of APAP-Cys, for on-column concentrations from 0.078 to 40.000 μg, ranged from ~83% to ~91.0% of the added amount (see Table 1). The linear equations and corresponding coefficient of determination () values for solutions of APAP-Cys in liver matrix protein and in distilled were, respectively, and . The lowest concentrations of APAP-Cys that could be detected (i.e., limit of detection) and accurately measured (i.e., limit of quantification) by the proposed method amounted to 0.06 μg and 0.14 μg (on column), respectively, at a signal-to-noise ratio of at least 2 : 1.
3.4. Precision and Accuracy
Intraday variability was assessed by using the proposed method to analyze samples of APAP-Cys, added as a spike to distilled water and to liver matrix protein, at three different levels (i.e., 0.156, 0.625, 1.250 μg) and at three different times within the same day. As shown in Table 2, the RSD values ranged from 0.52 to 0.91% for samples in water and from 0.63% to 1.02% for samples in matrix protein. Evaluation of method interday variability was carried out using the sample solutions used in the intraday variability study. In this case, each sample solution was analyzed once daily, for three consecutive days. As shown in Table 3, the RSD values for samples in water and in matrix protein were in the range 0.60 to 0.87% and 1.05 to 1.32%, respectively.
3.5. Tissue Sample Analysis to Evaluate the Effect of APAP Antidotes on APAP-Cys Formation
To test the suitability of the proposed HPLC method for measuring the levels of APAP-Cys adduct formation in the liver in the course of evaluating pharmacological agents with potential for use as antidotes against APAP overdose, rats were intraperitoneally treated with a dose of APAP (800 mg/kg) reported to be hepatotoxic in this animal species . Two additional groups of rats received NAC or TAU, in a 2.4 mmol/kg i.p. dose, 30 min before a treatment with APAP. While NAC is the most widely accepted antidote for cases of APAP overdose [14, 15], TAU has shown prophylactic and therapeutic effects in APAP-induced hepatic injury, apoptosis, and necrosis . In the absence of an antidote, a discernible peak with a retention time (~22.5 min) comparable with that of an authentic sample of APAP-Cys, and yielding an area equivalent to 19 μg/g of liver sample, was observed at 6 hr after a treatment with APAP. In contrast, this chromatographic peak was not detected in livers from rats treated with either NAC or TAU ahead of APAP.
The HPLC method presented here should prove useful in animal studies aimed at verifying the formation of APAP-protein adducts following a treatment with a toxic dose of APAP as well as the effect of compounds and substances with potential for use as an antidote against APAP overdosing. Salient features of this method are a sample preparation approach based on centrifugal ultrafiltration that minimizes procedural steps and reagents and permits the isolation of APAP-protein adducts in a rapid manner and with a high degree of purity and yield. Except for an overnight protease digestion step, one complete analysis can be completed in less than 2 hr. Hence, the proposed method will be quite suited in APAP-related studies with small animals and requiring the analysis of multiple samples.
- L. J. Chun, M. J. Tong, R. W. Busuttil, and J. R. Hiatt, “Acetaminophen hepatotoxicity and acute liver failure,” Journal of Clinical Gastroenterology, vol. 43, no. 4, pp. 342–349, 2009.
- W. M. Lee, “Acetaminophen toxicity: changing perceptions on a social/medical issue,” Hepatology, vol. 46, no. 4, pp. 966–970, 2007.
- S. D. Nelson and S. A. Bruschi, “Mechanisms of acetaminophen-induced liver disease,” in Drug-Induced Liver Disease, N. Kaplowitz and L. D. DeLeve, Eds., pp. 287–326, Marcel Decker, New York, NY, USA, 2003.
- J. A. Hinson, S. L. Pike, N. R. Pumford, and P. R. Mayeux, “Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice,” Chemical Research in Toxicology, vol. 11, no. 6, pp. 604–607, 1998.
- T. J. Davern, L. P. James, J. A. Hinson et al., “Measurement of serum acetaminophen-protein adducts in patients with acute liver failure,” Gastroenterology, vol. 130, no. 3, pp. 687–694, 2006.
- D. W. Roberts, N. R. Pumford, and D. W. Potter, “A sensitive immunochemical assay for acetaminophen-protein adducts,” Journal of Pharmacology and Experimental Therapeutics, vol. 241, no. 2, pp. 527–533, 1987.
- N. R. Pumford, J. A. Hinson, D. W. Potter, K. L. Rowland, R. W. Benson, and D. W. Roberts, “Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen adducts in serum and liver proteins of acetaminophen-treated mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 248, no. 1, pp. 190–196, 1989.
- L. P. James, H. C. Farrar, J. E. Sullivan et al., “Measurement of acetaminophen-protein adducts in children and adolescents with acetaminophen overdoses,” Journal of Clinical Pharmacology, vol. 41, no. 8, pp. 846–851, 2001.
- N. R. Pumford, J. A. Hinson, R. W. Benson, and D. W. Roberts, “Immunoblot analysis of protein containing 3-(cystein-S-yl)acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice,” Toxicology and Applied Pharmacology, vol. 104, no. 3, pp. 521–532, 1990.
- K. L. Muldrew, L. P. James, L. Coop et al., “Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxlc doses of acetaminophen using high-performance liquid chromatography with electrochemical detection,” Drug Metabolism and Disposition, vol. 30, no. 4, pp. 446–451, 2002.
- M. C. Damsten, J. N. M. Commandeur, A. Fidder et al., “Liquid chromatography/tandem mass spectrometry detection of covalent binding of acetaminophen to human serum albumin,” Drug Metabolism and Disposition, vol. 35, no. 8, pp. 1408–1417, 2007.
- H. Okabe, Y. Uji, H. Sugiuchi, Y. Watazu, Y. Shirahase, and N. Kaneda, “Optimal conditions for protease use in the assay of serum mitochondrial aspartate aminotransferase,” Journal of Clinical Laboratory Analysis, vol. 4, no. 5, pp. 350–354, 1990.
- E. Waters, J. H. Wang, H. P. Redmond, Q. D. Wu, E. Kay, and D. Bouchier-Hayes, “Role of taurine in preventing acetaminophen-induced hepatic injury in the rat,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 280, no. 6, pp. G1274–G1279, 2001.
- D. P. Betten, F. L. Cantrell, S. C. Thomas, S. R. Williams, and R. F. Clark, “A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning,” Annals of Emergency Medicine, vol. 50, no. 3, pp. 272–279, 2007.
- K. Herren and S. Clarke, “Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Vomiting in paracetamol overdose,” Emergency Medicine Journal, vol. 19, no. 3, pp. 247–248, 2002.